“…Metastatic MCC has, of course, the worst prognosis, with 5‐year overall survival estimates of 14%‐25%, compared to 51%‐75% for localised disease 2,5 . Nevertheless, metastatic cases are extremely rare (6%‐8% of MCC), and fewer than 10 cases of pleural effusion containing MCC cells have been reported in the literature 6,7 . Cases reporting MCC pleural metastases associated with another neoplasia are even rarer, which can lead to diagnosis difficulty.…”